The stock of Xeris Biopharma Holdings Inc (XERS) has seen a 5.71% increase in the past week, with a -8.42% drop in the past month, and a -29.66% decrease in the past quarter. The volatility ratio for the week is 5.23%, and the volatility levels for the past 30 days are at 5.28% for XERS. The simple moving average for the last 20 days is 1.66% for XERS stock, with a simple moving average of -14.74% for the last 200 days.
Is It Worth Investing in Xeris Biopharma Holdings Inc (NASDAQ: XERS) Right Now?
Additionally, the 36-month beta value for XERS is 1.77. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for XERS is 132.54M and currently, short sellers hold a 6.75% ratio of that float. The average trading volume of XERS on May 09, 2024 was 1.86M shares.
XERS) stock’s latest price update
Xeris Biopharma Holdings Inc (NASDAQ: XERS)’s stock price has plunge by -1.60relation to previous closing price of 1.88. Nevertheless, the company has seen a 5.71% surge in its stock price over the last five trading sessions. Proactive Investors reported 2024-05-06 that Xeris Biopharma Holdings (NASDAQ:XERS) and Beta Bionics have announced an exclusive worldwide collaboration and license agreement aimed at revolutionizing diabetes management. The partnership seeks to leverage Xeris’ novel XeriSol technology for the development and commercialization of a glucagon product to be integrated into Beta Bionics’ proprietary bi-hormonal pump and pump systems.
Analysts’ Opinion of XERS
Many brokerage firms have already submitted their reports for XERS stocks, with Oppenheimer repeating the rating for XERS by listing it as a “Outperform.” The predicted price for XERS in the upcoming period, according to Oppenheimer is $5 based on the research report published on March 28, 2024 of the current year 2024.
Craig Hallum, on the other hand, stated in their research note that they expect to see XERS reach a price target of $4.50. The rating they have provided for XERS stocks is “Buy” according to the report published on August 28th, 2023.
Jefferies gave a rating of “Buy” to XERS, setting the target price at $4 in the report published on October 21st of the previous year.
XERS Trading at -13.34% from the 50-Day Moving Average
After a stumble in the market that brought XERS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.25% of loss for the given period.
Volatility was left at 5.28%, however, over the last 30 days, the volatility rate increased by 5.23%, as shares sank -6.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.89% lower at present.
During the last 5 trading sessions, XERS rose by +5.71%, which changed the moving average for the period of 200-days by -26.59% in comparison to the 20-day moving average, which settled at $1.8132. In addition, Xeris Biopharma Holdings Inc saw -21.28% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XERS starting from Schmid John P., who purchase 4,500 shares at the price of $2.16 back on Mar 14 ’24. After this action, Schmid John P. now owns 11,000 shares of Xeris Biopharma Holdings Inc, valued at $9,720 using the latest closing price.
SHERMAN JEFFREY W, the Director of Xeris Biopharma Holdings Inc, purchase 5,400 shares at $1.87 during a trade that took place back on Nov 27 ’23, which means that SHERMAN JEFFREY W is holding 5,400 shares at $10,098 based on the most recent closing price.
Stock Fundamentals for XERS
Current profitability levels for the company are sitting at:
- -0.27 for the present operating margin
- 0.81 for the gross margin
The net margin for Xeris Biopharma Holdings Inc stands at -0.38. The total capital return value is set at -0.18. Equity return is now at value -324.20, with -18.17 for asset returns.
Based on Xeris Biopharma Holdings Inc (XERS), the company’s capital structure generated 1.04 points at debt to capital in total, while cash flow to debt ratio is standing at -0.25. The debt to equity ratio resting at -28.67. The interest coverage ratio of the stock is -3.41.
Currently, EBITDA for the company is -30.85 million with net debt to EBITDA at -4.58. When we switch over and look at the enterprise to sales, we see a ratio of 2.66. The receivables turnover for the company is 4.18for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.64.
Conclusion
In conclusion, Xeris Biopharma Holdings Inc (XERS) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
